Want to see HYFT full AI Analyst Report?
Top Page
MindWalk Holdings
(NASDAQ:HYFT)
Select Model
Select Model
Rating:47Neutral
Price Target:
$1.50
▲(10.29% Upside)
Action:Reiterated
Date:07/25/26
The score is held down primarily by weak financial performance (ongoing losses, shrinking equity base, and persistent cash burn). Technical signals also remain bearish with the stock below major moving averages. Partially offsetting these risks, the latest earnings call pointed to improving operating trajectory (strong revenue growth, higher gross margins, initial recurring SaaS contracts, and operational gains), but profitability and cash runway remain key uncertainties.
Positive Factors
High Gross Margins
Sustained near-60% gross margins reflect a high-value, IP-driven product mix (HYFT/ReefIQ/LensAI) that separates cost of goods from scalable software and data services. If recurring platform adoption grows, these margin levels enable durable operating leverage and stronger cash conversion over time.
Negative Factors
Persistent Net Losses & Equity Erosion
Large, ongoing losses that materially erode shareholders' equity are a structural concern: continued negative retained earnings limits financial flexibility, raises dilution or refinancing risks, and constrains investments needed to scale the SaaS transition without materially altering capital structure.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margins
Sustained near-60% gross margins reflect a high-value, IP-driven product mix (HYFT/ReefIQ/LensAI) that separates cost of goods from scalable software and data services. If recurring platform adoption grows, these margin levels enable durable operating leverage and stronger cash conversion over time.
Read all positive factors
MindWalk Holdings (HYFT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$60.61M
Dividend YieldN/A
Average Volume (3M)281.09K
Price to Earnings (P/E)―
Beta (1Y)1.83
Revenue Growth-35.84%
EPS Growth67.41%
CountryUS
Employees102
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.31
Shares Outstanding46,987,297
10 Day Avg. Volume317,362
30 Day Avg. Volume281,090
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)6.39
Price to Sales (P/S)4.89
P/FCF Ratio-5.92
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.00Price Target Upside267.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.25
Revenue Forecast (FY)$20.47M
MindWalk Holdings Business Overview & Revenue Model
Company Description
MindWalk Holdings Corp. functions as an innovative bio-native artificial intelligence firm. Its core mission involves leveraging the synergy of AI, comprehensive multi-omics data, and sophisticated laboratory investigations to accelerate the ident...
MindWalk Holdings Earnings Call Summary
Earnings Call Date:Jul 22, 2026
(Q4-2026)
| % Change Since: |
Next Earnings Date:Sep 10, 2026
Earnings Call Sentiment Positive
The call presented a materially improved operational and commercial trajectory: revenue grew 46% with expanding gross margins, net loss was more than halved year-over-year, the company secured its first recurring platform contracts, launched ReefIQ, filed IP extensions, and demonstrated major infrastructure gains via the AMD partnership. However, the recurring revenue is still not material, the company remains unprofitable with a sizeable net loss (~$14–15M), operating expenses are increasing on a comparable basis and cash is modest relative to planned investments. On balance the progress, validation and strategic moves (patent, AMD engineering, Russell inclusion, FDA-linked client approval and nondilutive divestiture proceeds) outweigh the near-term financial challenges and execution risks.Positive Updates
Strong Revenue Growth
Total revenue increased 46% year-over-year to $15.6M for fiscal 2026 (from $10.6M). Q4 revenue was $4.1M, a 50% increase versus $2.7M in Q4 2025.
Negative Updates
Recurring Revenue Currently Immature
Although the first enterprise SaaS agreements were signed, management confirmed recurring platform revenue was not material to FY26’s $15.6M total and remains a small portion while fee-for-service still dominates.
Read all updates
Q4-2026 Updates
Positive
Negative
Strong Revenue Growth
Total revenue increased 46% year-over-year to $15.6M for fiscal 2026 (from $10.6M). Q4 revenue was $4.1M, a 50% increase versus $2.7M in Q4 2025.
Read all positive updates
Company Guidance
The company reiterated a clear FY2027 plan to scale recurring, high‑margin SaaS revenue while continuing to invest in its pipeline and ReefIQ data platform, warning operating expenses will rise as it makes those commercial and R&D investments; key metrics cited on the call included FY2026 revenue up 46% to $15.6M (Q4 $4.1M, +50% y/y), gross margin expanded to 59% for the year (61% in Q4), cash of $11.5M as of Apr 30, 2026 and nondilutive proceeds of US$10.3M from the European divestiture, with net loss narrowing to roughly $14–15.1M (loss per share $0.33 vs $0.99 prior year) and operating expenses of $24.1M (comparable increase ≈$4.2M), R&D $4.9M and sales & marketing $5.9M; commercial traction includes the first two contracted recurring LensAI platform agreements, double‑digit clients in the LensAI portal and dozens of programs moving into usage, a clinic record of 20+ molecules (10 in active Phase I–III, 4 first‑in‑class, >400 publications/patents), an AMD‑enabled throughput win (≈170,000 antibody pair screens in ~4.5 hours vs 145 days previously; literature‑mining cost per million samples down ~39%, embedding throughput +70%), Russell 3000E/Microcap inclusion and a July 1, 2026 patent filing to extend HYFT — and management said it will seek nondilutive funding for owned assets and only disclose material pipeline milestones as they are reached.MindWalk Holdings Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
21
Negative
| Breakdown | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 15.32M | 24.52M | 24.52M | 20.66M | 19.36M |
| Gross Profit | 9.01M | 13.55M | 12.05M | 11.56M | 10.98M |
| EBITDA | -13.13M | -28.86M | -22.95M | -21.04M | -11.99M |
| Net Income | -13.74M | -30.23M | -26.11M | -26.56M | -16.71M |
Balance Sheet | |||||
| Total Assets | 21.34M | 44.44M | 59.99M | 77.81M | 93.49M |
| Cash, Cash Equivalents and Short-Term Investments | 11.33M | 10.66M | 3.46M | 8.28M | 29.96M |
| Total Debt | 3.52M | 13.40M | 13.68M | 14.27M | 2.77M |
| Total Liabilities | 9.61M | 20.82M | 26.07M | 20.01M | 18.36M |
| Stockholders Equity | 11.73M | 23.63M | 33.92M | 57.80M | 75.28M |
Cash Flow | |||||
| Free Cash Flow | -12.66M | -7.21M | -5.64M | -21.33M | -11.18M |
| Operating Cash Flow | -12.27M | -6.41M | -4.25M | -19.83M | -9.92M |
| Investing Cash Flow | 13.34M | -799.00K | -1.56M | -1.97M | -5.21M |
| Financing Cash Flow | 113.23K | 14.89M | 1.02M | -621.00K | 2.88M |
MindWalk Holdings Technical Analysis
Negative
1.36
Price Trends
1.54
Negative
1.38
Negative
1.55
Negative
Market Momentum
-0.05
Positive
46.59
Neutral
55.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HYFT, the sentiment is Negative. The current price of 1.36 is below the 20-day moving average (MA) of 1.39, below the 50-day MA of 1.54, and below the 200-day MA of 1.55, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 46.59 is Neutral, neither overbought nor oversold. The STOCH value of 55.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HYFT.
MindWalk Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $556.97M | -4.78 | -71.22% | ― | ― | 55.59% | |
54 Neutral | $59.20M | -0.74 | -68.98% | ― | ― | -26.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $60.61M | -5.93 | -90.61% | ― | -35.84% | 67.41% | |
45 Neutral | $17.16M | -0.48 | -208.23% | ― | ― | 55.37% |
* Healthcare Sector Average
HYFT
MindWalk Holdings
1.36
-0.45
-24.86%
XBIT
XBiotech
2.24
-0.66
-22.76%
RLMD
Relmada Therapeutics
5.47
4.90
861.34%
PMVP
PMV Pharmaceuticals
1.17
-0.31
-20.95%
HOWL
Werewolf Therapeutics
0.41
-0.80
-65.79%
ESLA
Estrella Immunopharma
0.70
-0.15
-17.18%
MindWalk Holdings Corporate Events
MindWalk Unveils First Public ReefIQ Demo on AMD Instinct at Advancing AI 2026
Jul 23, 2026
On July 23, 2026, MindWalk Holdings Corp. used AMD’s Advancing AI 2026 event in San Francisco to debut the first public demonstration of ReefIQ, its biological context layer for AI-driven drug discovery, running on AMD Instinct accelerators....
MindWalk Holdings Posts 46% Revenue Surge as Pivot to Bio-Native AI Infrastructure Takes Hold
Jul 22, 2026
For the fiscal year ended April 30, 2026, MindWalk Holdings reported a 46% jump in revenue to $15.6 million, gross margin expansion to nearly 59%, and a net loss reduced by more than half to $13.9 million, as the company completed its pivot from b...
MindWalk Holdings Sets July 22, 2026 Date to Report FY 2026 Results and Business Highlights
Jul 13, 2026
MindWalk Holdings Corp., a Bio-Native AI specialist serving the life sciences sector, has developed a proprietary HYFT technology that encodes 660 million biological patterns and 25 billion relationships, forming the foundation for its ReefIQ data...
MindWalk Holdings Added to Russell 3000E Index, Boosting Bio-Native AI Visibility
Jul 6, 2026
MindWalk Holdings Corp. said it has been added to the Russell 3000E Index following the FTSE Russell U.S. index reconstitution that took effect after the market close on June 26, 2026. Membership, reconfirmed in data published June 29, 2026, place...
MindWalk Files European Patent for High-Dimensional Biological Data Layer Powering AI Drug Discovery
Jul 1, 2026
MindWalk Holdings has filed a new European patent application covering high-dimensional biological data structures that support its HYFT technology, ReefIQ context layer, and LensAI reasoning workflows, according to a July 1, 2026 announcement. Th...
MindWalk CEO to Join Jones AI Day Panel on Future of AI Drug Discovery
Jun 12, 2026
On June 12, 2026, MindWalk Holdings announced that President and CEO Dr. Jennifer Bath will join a virtual Jones AI Day panel on June 15, 2026, alongside Absci and a major AI compute provider, to discuss the convergence of high-performance compute...
MindWalk Holdings Unveils ReefIQ Context Layer to Power AI Drug Discovery
Jun 10, 2026
On June 10, 2026, MindWalk Holdings Corp. launched ReefIQ, a HYFT-powered biological context layer designed to sit between clients’ drug-discovery data and AI reasoning workflows, reconnecting fragmented sequences, structures, assays, omics,...
MindWalk Showcases HYFT® Platform With Pan-Serotype Dengue Preclinical Data
Jun 2, 2026
MindWalk Holdings on June 2, 2026 reported preclinical dengue results showing that immunogens designed by its HYFT® AI platform elicited antibodies that bound antigens from all four dengue serotypes in animals. The cross-reactive binding patt...
MindWalk Holdings Launches AI-Driven Pandemic Response Platform for RNA Virus Outbreaks
May 27, 2026
MindWalk Holdings Corp., a bio-native AI therapeutic research and technology company listed on Nasdaq, develops the HYFT biological pattern system and LensAI platform as an AI-ready substrate for life sciences data and decision-making. Its Knowled...
MindWalk Highlights 20-Plus Partner Drug Programs Tied to Its Discovery Platform
May 18, 2026
MindWalk Holdings Corp., which integrates proprietary HYFT biological intelligence infrastructure with a wet-lab antibody discovery engine, operates laboratories in Victoria, British Columbia, AI and technology operations in Belgium, and U.S. offi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.